Lyell Immunopharma (NASDAQ:LYEL) Trading 13.4% Higher – What’s Next?

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) traded up 13.4% during trading on Thursday . The stock traded as high as $27.27 and last traded at $27.3550. 18,234 shares traded hands during trading, a decline of 83% from the average session volume of 108,277 shares. The stock had previously closed at $24.12.

Analyst Ratings Changes

Several research analysts recently issued reports on LYEL shares. HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and upped their price target for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $45.00.

Lyell Immunopharma Trading Up 7.1%

The stock has a market capitalization of $548.84 million, a P/E ratio of -1.12 and a beta of -0.13. The company has a fifty day simple moving average of $26.81 and a two-hundred day simple moving average of $18.09.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.81) by $0.68. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. As a group, analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ARCH Venture Management LLC bought a new stake in shares of Lyell Immunopharma in the 2nd quarter valued at about $16,113,000. Acadian Asset Management LLC boosted its stake in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after acquiring an additional 443,614 shares during the last quarter. Vanguard Group Inc. grew its holdings in Lyell Immunopharma by 76.0% during the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after purchasing an additional 336,378 shares during the period. AQR Capital Management LLC increased its stake in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after purchasing an additional 154,327 shares in the last quarter. Finally, RBF Capital LLC acquired a new stake in Lyell Immunopharma in the second quarter worth $884,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.